VRCA

Verrica Pharmaceuticals Inc.

BS score —UNSCOREDPHASE3 · mkt cap $100.2M · rev ttm $35.6M

drug hypothesis

Cantharidin modulates Not clearly specified - topical caustic/blistering agent targeting lesional skin rather than a specific molecular target to treat Molluscum Contagiosum.

moa:Topical caustic agent derived from blister beetles that induces blistering and destruction of molluscum lesions through local cytotoxic action

score breakdown

trial design0

base rate disconnect0

language red flags0

composite—

valuation analysis

market cap$100.2M

revenue ttm$35.6M

phasePHASE3

historical base rate—

disconnect ratio—

lead trialNCT03377790

meta

cik0001660334

first discovered2026-04-10

last updated2026-04-10

statusACTIVE

llm modelminimax/minimax-m2.5:free

extracted at2026-04-10

trial design

Phase 3, randomized, quadruple-blind, placebo-controlled trial enrolling 266 patients with molluscum contagiosum; cantharidin application versus placebo with assessments at Days 21, 42, 63, and 84

primary endpoint:Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on Day 84 visit (end of study)

claimed differentiation

Not stated in available data

language red flags

Very limited information provided in filing - no business context, company identification, or development strategy disclosed
No stated differentiation claims or competitive positioning provided
No financial or operational details included in excerpt